Peter Dobranowski

MSc, PhD(c) | Precision Microbiome IBD
opinions my own

[Peter Dobranowski @PDobrano]

What's next: we used our ex vivo microbiome culturing platform (RapidAIM) to personalize RS in clinical trials. Trials are complete and analyses are ongoing.

A big thank you to all collaborators, technicians, and patients and their families for enabling this work.

[Peter Dobranowski @PDobrano]

Happy to announce the first chapter of my PhD is published open access in @Nature_NPJ: https://t.co/T63bN6hYXS 🧵

[Peter Dobranowski @PDobrano]

Our new paper adds:
- RS-specific fermentation profiles
- Microbiomes from kids with IBD ferment RS with high inter-individual variability
- Broad microbiome functions are activated by RS, beyond butyrate (nucleic acids, fatty acids, amino acids, and derivatives)

[Peter Dobranowski @PDobrano]

@srmbeauroy @bottomlineibd @policritic Strong disease-level conclusions, with residuals perhaps explained by e.g. diet x gene x microbiome x psych x medication interactions. I anticipate future PREdiCCt studies will leverage these interactions to cut through noise and arrive closer to individualized predictions.

[Peter Dobranowski @PDobrano]

@IldikoMe Nonetheless, metagenomics on the removed appendices seems like low-hanging fruit to predict responders/non-responders.

[Peter Dobranowski @PDobrano]

@IldikoMe I was excited to read this as an indictment on the microbiome, but certainly tempered by the nuance - appendicectomy was adjunct to biologics, and 80% of the control group was given Tofa 10mg. E.g. outcomes would be different without adjunct biologics or with a 100% Upad control.

[Erik Hoel @erikphoel]

Writing this made me feel better this week. I hope reading it makes you feel better.

https://t.co/F7gZYg3ump

[Peter Dobranowski @PDobrano]

This is not a totally surprising outcome of precision medicine (and may be useful in certain contexts): patients predicted to respond to a therapy may simply fare better without the therapy to begin with.

[Peter Dobranowski @PDobrano]

2025 @NEJM study by @bruce_sands1 et al reports efficacy and safety of anti-TL1A (Tulisokibart) in moderate-severe #UC. Notably, they evaluated patient stratification using a gene-variant machine learning algorithm.

https://t.co/7PST3ucH9x

[Peter Dobranowski @PDobrano]

Clinical remission was more likely in “predicted responders” (32%) than non-stratified patients (26%). But, clinical remission was also more likely in “predicted responders” randomized to the placebo group (11%) than non-stratified placebo patients (1%).

[Peter Dobranowski @PDobrano]

Given that gut barrier dysfunction can precede IBD diagnosis by years, the role of butyrate remains a critical part of IBD research: as a biomarker of disease, and therapeutic lever through personalized diet, next-gen probiotics, and FMT.
10.1016/j.clnu.2022.10.024

[Peter Dobranowski @PDobrano]

From 2025 @Gut_BMJ, Hazime et al @ibddocmaria untangle more of DUOX2’s role in early / subclinical #IBD, with new evidence of #butyrate’s role in maintaining gut homeostasis

https://t.co/JTazywxwAr

[Peter Dobranowski @PDobrano]

But, this vicious cycle parallels a virtuous cycle – treating these dysbiotic mice with butyrate reversed DUOX2 upregulation, epithelial permeability, and subclinical inflammation.